Wockhardt Ltd, which recently undertook a debt restructuring scheme, has signed an agreement to divest its non-core nutritional business to Abbott, a global healthcare company. Sources said the deal was worth close to $130 million (Rs 625 crore).
The company’s nutrition business includes some of the major child care brands, such as Farex, Dexolac and Nusobee infant formulas, and Farex weaning cereal. The adult protein supplement, Protinex, is a segment leader in the vitamin and health supplement category.
Wockhardt had acquired Dumex
Wockhardt’s over Rs 3,400 crore debt was restructured by its lenders in June. As per the corporate debt restructuring (CDR) scheme, it has to divest its non-core assets at an estimated value of Rs 790 crore, within the next six years. It had already mobilised close to Rs 300 crore from the recent sale of its loss-making German subsidiary, Esparma, to Mova GmbH and the animal health division to Vétoquinol, a French veterinary care company.
The company is also looking at divesting a 32-acre dairy and milk processing unit in Punjab which the company inherited from its acquisition of Dumex
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |